Table 1.

Study outcomes

ReferenceStudy arms (risk group in case of stratification)NICH in sibling, n (%)FBS, n (%)IUPT, n (%)FBS/IUPT-related AE, n (%)Duration IVIG, wk, mean (range)SE IVIG/ steroids, n (%)ICH, n (%)Mean PLTs × 109/LPLT < 50 × 109/L, n (%)Mortality, n (%)
Randomized controlled trials
30IVIG 0.5 g12000NA10 (7-11)00813 (25)0
IVIG 1 g11000NA11 (7-12)001104 (36)0
37IVIG 2 g370All02 (5)16 (11-20)12 (32)11695 (14)0
IVIG 1 g + steroids360All02 (6)16 (12-19)13 (33)11344 (11)0
35IVIG (all)404 (10)All011 (14)NRNR3104NR4 (5)
IVIG + steroids (high)193 (16)All0NRNR99NR
Steroids (standard)200All0NANR108NR
20IVIG*286 (21)All05 (9)100096<30 6 (21)5 (9)
IVIG + steroids264 (15)All0112 (8)0110<30 5 (19)
Prospective studies
17IVIG ± IUPT77 (100)3 (43)3 (43)NR17 (8-21)NR0287 (100)0
39IUPT predelivery20All2 (100)NRNANA021000
IVIG ± IUPT402 (50)2 (50)NR17 (15-19)NR020400
IVIG + steroids132 (15)1 (8)1 (8)NR12 (5-20)NR01184 (31)0
18IVIG ± IUPT378 (19)26 (70)26 (70)05 (2-15)NR06717 (46)0
FBS ± IUPT13All9 (69)2 (22)NANA0327 (54)1 (8)
23IVIG83 (30)AllNR2 (20)12 (3-16)NR0NR1 (13)0
Fetal IVIG2AllNR2 (1-2)NR0NR2 (100)0
22IVIG95 (56)All1 (11)NRNRNR0574 (44)NR
IVIG + steroids93 (33)8 (89)0NRNR5 (56)0643 (33)NR
Retrospective studies
31IVIG 1 g (all)52 (40)00NANR01§638 (67)0
IVIG 0.5 g (standard)17000NANR001044 (33)0
32IVIG279 (14)00NA14NR08912 (44)0
IVIG + steroids5400NA14NR013513 (27)0
Steroids1100NANANR0468 (73)0
24IVIG175 (29)901 (11)12NR06810 (59)0
IVIG + steroids6000NA7NR0784 (67)0
19IVIG 1 g (high + very high)55 (100)All1 (17)3 (8)15 (7-25)NR116500
IVIG 1 g + steroids (all)1919 (100)All012 (5-25)NR3856 (40)2 (11)
IVIG 2 g (all)44 (100)All022 (18-25)NR011200
IVIG 2 g + steroids (all)99 (100)All023 (18-27)NR113500
21Fetal IVIG + IUPT10NRAll10 (100)010 (6-14)NR018900
26IVIG135 (38)NR2 (15)NRNRNR0836 (46)0
34IVIG (all)535 (9)00NA8 (2-24)NR012510 (19)0
FBS + IVIG (all)3311 (33)AllNR3 (7)6 (2-21)NR017401 (3)
FBS + IUPT (standard)130All13 (100)0NANA01453 (23)0
41IUPT ± IVIG ± steroids40NRAll40 (100)3 (8)NRNR4107NR6 (15)
IVIG and/or steroids7NRNR01 (14)NRNR07-219NR1 (14)
No treatment8NRNANANANANA06-84NR0
38IVIG2404 (17)0NR15 (9-19)NR0118<30 2 (8)0
No treatment60NANANANANA024<30 4 (67)0
27IVIG*95 (56)00NANRNR0904 (44)0
IUPT30All3 (100)3 (100)NANA0472 (100)1 (33)
No treatment62 (34)00NANANA194 (80)1 (17)
28IVIG ± IUPT*186 (60)All6 (33)3 (17)9 (1-19)1 (6)1§816 (33)0
IUPT weekly3111 (42)All31 (100)10 (30)NANA2§NRNR3 (10)
FBS ± single IUPT70All5 (71)2 (29)NANA0NRNR0
42IVIG ± IUPT*111 (9)All9 (82)2 (18)6 (1-12)1 (9)01095 (45)0
IUPT40All4 (100)2 (50)NANA0762 (50)0
29IVIG277 (26)All1 (4)NR7 (2-15)NR26913 (48)2 (7)
Steroids10NRAllNRNRNANRNRNR6 (60)NR
33IVIG + IUPT41 (25)All4 (100)1 (25)NR0018201 (25)
IVIG61 (17)All01 (17)NR00982 (33)1 (17)
40IVIG + IUPT ± steroids86 (75)All6 (100)1 (13)9 (4-17)NR1§34002 (25)
IUPT ± steroids75 (71)All7 (100)0NANR2§30501 (14)
36IVIG2NRAll0NR14 (13-14)00601 (50)0
IVIG + steroids4NRAll0NR11 (5-20)0014600
25IUPT41 (20)All5 (100)0NANA020000
IVIG (5 d) + IUPT10All1 (100)050010700
  • AE, adverse event; NA, not applicable; NR, not reported; SE, side effect.

  • * One or 2 patients also received steroids (supplemental Table 1).

  • Five fetuses exsanguinated and were excluded from other analyses.

  • Platelet count before predelivery IUPT.

  • § ICH occurred before start of therapy.

  • Platelet count after IUPT.